Diagnostik und Therapie der akuten myeloischen Leukämie

Die Untersuchungen zur Diagnosesicherung und Subklassifizierung der akuten myeloischen Leukämie (AML) beinhalten heute eine Kombination aus zytomorphologischen sowie zyto- und molekulargenetischen Untersuchungen. Diese sind die Voraussetzung für eine adäquate Therapie, die vorgenommen werden sollte, um den Therapiestandard sicherzustellen und um die therapeutischen Möglichkeiten innerhalb klinischer Studien weiter zu verbessern.

Literatur

• 1 Bennett J M, Catovsky D, Daniel M T. et al . Proposals for the classification of the acute leukaemias. French- American-British (FAB) co-operative group.  Br J Haematol. 1976;  33 451-458
• 2 Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press 2001
• 3 Haferlach T, Schoch C, Schnittger S, Kern W, Loffler H, Hiddemann W. Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study on 124 patients.  Br J Haematol. 2002;  118 426-431
• 4 Haferlach T, Schoch C. WHO classification of acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS).  Dtsch Med Wochenschr. 2002;  127 447-450
• 5 Schoch C, Haferlach T, Haase D. et al . Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.  Br J Haematol. 2001;  112 118-126
• 6 Grimwade D, Walker H, Oliver F. et al . The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties.  Blood. 1998;  92 2322-2333
• 7 Schoch C, Kern W, Krawitz P. et al . Dependence of age-specific incidence of acute myeloid leukemia on karyotype.  Blood. 2001;  98 3500
• 8 Lengfelder E, Reichert A, Schoch C. et al. German AML Cooperative Group . Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia.  Leukemia. 2000;  14 1362-1370
• 9 Ostermann H, Derigs H G, Heussel G. et al . Sepsis in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association for Hematology and Oncology.  Dtsch Med Wochenschr. 1999;  124 S14-S17 (Suppl 1)
• 10 Buchner T, Hiddemann W, Wormann B. et al . Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group.  Blood. 1999;  93 4116-4124
• 11 Kern W, Haferlach T, Schoch C. et al . Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group 1992 Trial.  Blood. (in press); 
• 12 Hiddemann W, Kern W, Schoch C. et al . Management of acute myeloid leukemia in elderly patients.  J Clin Oncol. 1999;  17 3569-3576
• 13 Mayer R J, Davis R B, Schiffer C A. et al. Cancer and Leukemia Group B . Intensive postremission chemotherapy in adults with acute myeloid leukemia.  N Engl J Med. 1994;  331 896-903
• 14 Buchner T, Urbanitz D, Hiddemann W. et al . Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.  J Clin Oncol. 1985;  3 1583-1589
• 15 Cassileth P A, Harrington D P, Appelbaum F R. et al . Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission (see comments).  N Engl J Med. 1998;  339 1649-1656
• 16 Kern W, Schoch C, Fonatsch C. et al . Therapie der akuten myeloischen Leukämie bei Patienten im höheren Lebensalter.  Dtsch Med Wochenschr. 1999;  124 1005-1014
• 17 Leith C P, Kopecky K J, Godwin J. et al. A Southwest Oncology Group study . Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy.  Blood. 1997;  89 3323-3329